Alexandria is
leading the creation of a public-private partnership on biomarkers
for depression, which
aims to develop a modernized, data-driven framework for
guiding patients with depression to the
therapies most likely to benefit them
PASADENA, Calif., May 6, 2024
/PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE),
the first, preeminent, longest-tenured and pioneering owner,
operator and developer of collaborative life science mega campuses
in AAA innovation cluster locations, is leveraging its unique
position at the vanguard and heart of the $5
trillion secularly growing life science industry and
coalescing its world-class life science and healthcare networks to
drive forward action- and solutions-oriented corporate
responsibility initiatives aimed at prioritizing the devastating
and pervasive mental health crisis. During Mental Health Awareness
Month, a time dedicated nationally to increase awareness of the
challenges faced by millions of Americans living with mental health
conditions, Alexandria reaffirms
its mission-critical goals to meaningfully address the urgent need
to (1) break the stigma around mental illness and addiction, (2)
promote mental health as essential to overall health and (3) help
accelerate the development of innovative new treatments.
"Our nation is grappling with an unprecedented mental health
crisis. For context, if you were standing in a packed stadium that
represented our country, 1 out of every 5 adults and 1 out of every
6 youth (aged 6–17) would have recently experienced depression,
anxiety or another mental health condition, yet only about half of
them would have received treatment," said Lynne Zydowsky, PhD, chief of science at
Alexandria Real Estate Equities, Inc. and Alexandria Venture
Investments. "During Mental Health Awareness Month, we call for
increased attention and policy action at the federal, state and
local levels to transform the way we diagnose, treat and discuss
mental illness. Mental health touches everyone in some way, and we
must ensure all Americans, especially our youth, have access to the
care they need while we work to cultivate partnerships and impact
policy to accelerate innovation that saves lives."
Reducing the stigma of mental illness and addiction is critical
in empowering people to seek lifesaving help. The mental health
stigma is particularly relevant for military personnel and
veterans. Approximately 60% of military personnel with mental
health concerns do not seek treatment, and on average over 17
veterans are lost to suicide each day in the United States. Since 2010, Alexandria has been partnering with the Navy
SEAL Foundation and enabling it to meet the specific mental health
needs of these elite warriors. Alexandria played an instrumental role in the
establishment of the foundation's Warrior Fitness Program West
Coast facility in San Diego, which
provides Navy SEAL warriors and veterans with access to
evidence-based support, advanced performance and fitness technology
and expert personnel to help them physically and mentally recover
and rebuild from injuries and trauma. Additionally, the comorbidity
of individuals with severe mental disorders and substance use is
roughly 50%. In 2017, Alexandria
and Verily pioneered OneFifteen, a first-of-its-kind evidence-based
comprehensive care model for treating addiction. OneFifteen has
treated over 7,500 patients since opening in 2019. Drug overdose
deaths reached 111,000 last year, largely due to the increasing
influx of fentanyl, highlighting the immense need for a sustainable
approach to address addiction.
Never has it been more essential to recognize the importance of
mental health to overall health. Studies have shown that the
presence of mental disorders increases the risk of numerous
comorbidities such as diabetes and obesity. The life science
industry has displayed a resurgence of commercial interest and
progress in developing medicines for mental health disorders, as
demonstrated by the recent advancement of multiple
paradigm-shifting psychiatric medicines. These advances include the
first FDA-approved oral treatment for postpartum depression from
Alexandria tenants Biogen and Sage
Therapeutics and recent positive clinical data from Alexandria tenant Intra-Cellular Therapies for
an adjunctive therapy to antidepressants for the treatment of major
depressive disorder.
Alexandria continues to convene
key life science industry influencers and policymakers to help
accelerate the development of innovative new psychiatric medicines
to address vast unmet need. The company, in partnership with former
congressman Patrick J. Kennedy and
The Kennedy Forum, has held two mental health-focused Alexandria
Summit® events, including its most recent summit in
Washington, D.C. this February. As
a tangible outcome of its inaugural mental health summit in 2023,
Alexandria has been leading the
creation of a public-private partnership (PPP) on biomarkers for
depression through the formation of a dedicated working group
consisting of government, industry, academic, non-profit and
patient advocacy leaders. This proposed PPP aims to utilize a
biomarker-driven approach with potential to revolutionize clinical
trials by identifying patient populations who are most likely to
demonstrate meaningful responses in a trial and also developing
modernized, data-driven measures that will accelerate the
development of innovative new treatments with greater
precision.
Alexandria is committed to
catalyzing meaningful change for the millions of individuals
struggling with mental illness. If you or someone you know is in
crisis, call or text 988 to reach the 988 Suicide & Crisis
Lifeline.
About Alexandria Real Estate Equities, Inc.
Alexandria
Real Estate Equities, Inc. (NYSE: ARE), an S&P
500® company, is a best-in-class, mission-driven
life science REIT making a positive and lasting impact on the
world. As the pioneer of the life science real estate niche since
our founding in 1994, Alexandria
is the preeminent and longest-tenured owner, operator and developer
of collaborative life science mega campuses in AAA innovation
cluster locations, including Greater
Boston, the San Francisco Bay
Area, San Diego,
Seattle, Maryland, Research Triangle and New York City. Alexandria has a total market capitalization
of $34.4 billion and an asset base in
North America of 74.1 million SF
as of March 31, 2024, which includes
42.2 million RSF of operating properties, 5.3 million RSF of Class
A/A+ properties undergoing construction and one committed near-term
project expected to commence construction in the next two years,
2.5 million RSF of priority anticipated development and
redevelopment projects, and 24.1 million SF of future development
projects. Alexandria has a
longstanding and proven track record of developing Class A/A+
properties clustered in life science mega campuses that provide our
innovative tenants with highly dynamic and collaborative
environments that enhance their ability to successfully recruit and
retain world-class talent and inspire productivity, efficiency,
creativity and success. Alexandria
also provides strategic capital to transformative life science
companies through our venture capital platform. We believe our
unique business model and diligent underwriting ensure a
high-quality and diverse tenant base that results in higher
occupancy levels, longer lease terms, higher rental income, higher
returns and greater long-term asset value. For more information on
Alexandria, please
visit www.are.com.
Forward-Looking Statements
This press release includes "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
Such forward-looking statements include, without limitation,
statements regarding the impact of Alexandria's corporate responsibility and
thought leadership initiatives, practices, investments and
progress, the likelihood of continued support, investment and
partnership by Alexandria and the
potential impacts of such activities on Alexandria's business and tenants, the
companies and non-profit organizations in which Alexandria invests or with which Alexandria has strategic relationships,
medicines for mental health disorders and the country's mental
health and addiction crises. These forward-looking statements are
based on Alexandria's present
intent, beliefs or expectations, but forward-looking statements are
not guaranteed to occur and may not occur. Actual results may
differ materially from those contained in or implied by
Alexandria's forward-looking
statements as a result of a variety of factors, including, without
limitation, the risks and uncertainties detailed in its filings
with the Securities and Exchange Commission. All forward-looking
statements are made as of the date of this press release, and
Alexandria assumes no obligation
to update this information. For more discussion relating to risks
and uncertainties that could cause actual results to differ
materially from those anticipated in Alexandria's forward-looking statements, and
risks and uncertainties to Alexandria's business in general, please refer
to Alexandria's filings with the
Securities and Exchange Commission, including its most recent
annual report on Form 10-K and any subsequently filed quarterly
reports on Form 10-Q.
CONTACT: Joel S. Marcus, Executive Chairman
& Founder, (626) 578-9693, jmarcus@are.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/alexandria-real-estate-equities-inc-drives-forward-its-action--and-solutions-oriented-corporate-responsibility-initiatives-aimed-at-prioritizing-the-staggering-mental-health-crisis-during-mental-health-awareness-month-302136218.html
SOURCE Alexandria Real Estate Equities, Inc.
